Artículo de Revisión
182
Obesidad y enfe rmedad inf lama toria in tes tina l - C. Estay H. et al.
Conclusión
La comorbilidad entre obesidad y EII es alta y ha
ido aumentando en el tiempo, similar a lo que ocurre
en la población general. Establecer una asociación de
causalidad es difícil, sin embargo, ambas entidades
comparten factores patogénicos, específicamente la
disbiosis. Si se considera que la obesidad es un factor
modificable, es fundamental prevenir e intervenir activamente,
derivar en forma oportuna y educar a los
pacientes continuamente.
Si bien la literatura es escasa en cuanto a la relación
de obesidad y EII, actualmente los estudios
han sido enfocados al rol del tejido adiposo visceral,
planteando que la obesidad sería un marcador de enfermedad
grave y un factor de falla en la respuesta al
tratamiento. Considerando esta información, parece
prudente realizar una evaluación del estado nutricional
en el control ambulatorio de los pacientes con EII
mediante el índice cintura-cadera o una bioimpedanciometría
con el fin de optimizar el manejo de estos
pacientes.
Referencias
1.- GBD 2015 Obesity Collaborators, Afshin
A, Forouzanfar MH, Reitsma MB, Sur P,
Estep K, Lee A, et al. Health effects of
overweight and obesity in 195 countries
over 25 years. N Engl J Med 2017; 377:
13-27.
2.- Ministerio de Salud. Encuesta Nacional
de Salud ENS 2009-2010. Disponible
en: http://web.minsal.cl/portal/url/item/
bcb03d7bc28b64dfe040010165012d23.
pdf (Consultado el 10 de julio de 2017).
3.- Burisch J, Munkholm P. The
epidemiology of inflammatory bowel
disease. Scand J Gastroenterol 2015; 50:
942-51.
4.- Molodecky NA, Soon IS, Rabi DM,
Ghali WA, Ferris M, Chernoff G, et al.
Increasing incidence and prevalence
of the inflammatory bowel diseases
with time, based on systematic review.
Gastroenterology 2012; 142: 46-54.
5.- Cosnes J, Gower-Rousseau C, Seksik
P, Cortot A. Epidemiology and natural
history of inflammatory bowel diseases.
Gastroenterology 2011; 140: 1785-94.
6.- Simian D, Fluxá D, Flores L,
Lubascher J, Ibáñez P, Figueroa C,
et al. Inflammatory bowel disease: A
descriptive study of 716 local Chilean
patients. World J Gastroenterol 2016; 22:
5267-75.
7.- Damas OM, Avalos DJ, Palacio AM,
Gómez L, Quintero MA, Deshpande
AR, et al. Inflammatory bowel disease is
presenting sooner after immigration in
more recent US immigrants from Cuba.
Aliment Pharmacol Ther 2017; 46:
303-9.
8.- Benchimol EI, Mack DR, Guttmann
A, Nguyen GC, To T, Mojaverian N,
et al. Inflammatory bowel disease in
immigrants to Canada and their children:
a population-based cohort study. Am J
Gastroenterol 2015; 110: 553-63.
9.- Abegunde AT, Muhammad BH, Bhatti
O, Ali T. Environmental risk factors
for inflammatory bowel diseases:
Evidence based literature review. World J
Gastroenterol 2016; 22: 6296-317.
10.- Uranga JA, López-Miranda V, Lombó
F, Abalo R. Food, nutrients and
nutraceuticals affecting the course of
inflammatory bowel disease. Pharmacol
Rep 2016; 68: 816-26.
11.- Huguet JM, Suárez P, Ferrer-Barceló L,
Ruiz L, Monzó A, Durá AB, et al.
Endoscopic recommendations
for colorectal cancer screening
and surveillance in patients with
inflammatory bowel disease:
Review of general recommendations.
World J Gastrointest Endosc 2017; 9:
255-62.
12.- Arnold M, Pandeya N, Byrnes G,
Renehan AG, Stevens GA, Ezzati M,
et al. Global burden of cancer attributable
to high body-mass index in 2012: a
population-based study. Lancet Oncol
2015; 16: 36-46.
13.- Bray GA, Kim KK, Wilding JPH;
World Obesity Federation. Obesity: a
chronic relapsing progressive disease
process. A position statement of the
World Obesity Federation. Obes Rev
2017; 18: 715-23.
14.- Gregor MF, Hotamisligil GS.
Inflammatory mechanisms in obesity.
Annu Rev Immunol 2011; 29: 415-45.
15.- Singh S, Dulai PS, Zarrinpar A,
Ramamoorthy S, Sandborn WJ. Obesity
in IBD: epidemiology, pathogenesis,
disease course and treatment outcomes.
Nat Rev Gastroenterol Hepatol 2017; 14:
110-21.
16.- Harper JW, Zisman TL. Interaction of
obesity and inflammatory bowel disease.
World J Gastroenterol 2016; 22: 7868-81.
17.- Moran C, Sheehan D, Shanahan F. The
changing phenotype of inflammatory
bowel disease. Gastroenterol Res Pract
2016; 2016: 1619053.
18.- Moran GW, Dubeau MF, Kaplan GG,
Panaccione R, Ghosh S. The increasing
weight of Crohn’s disease subjects in
clinical trials: a hypothesis-generatings
time-trend analysis. Inflamm Bowel Dis
2013; 19: 2949-56.
19.- Kugathasan S, Nebel J, Skelton JA,
Markowitz J, Keljo D, Rosh J, et al.
Body mass index in children with newly
diagnosed inflammatory bowel disease:
observations from two multicenter North
American inception cohorts. J Pediatr
2007; 151: 523-7.
20.- Chan SS, Luben R, Olsen A,
Tjonneland A, Kaaks R, Teucher B, et al.
Body mass index and the risk for Crohn’s
disease and ulcerative colitis: data from a
European Prospective Cohort Study (The
IBD in EPIC Study). Am J Gastroenterol
2013; 108: 575-82.
21.- Khalili H, Ananthakrishnan AN,
Konijeti GG, Higuchi LM, Fuchs CS,
Richter JM, et al. Measures of obesity
and risk of Crohn’s disease and ulcerative
colitis. Inflamm Bowel Dis 2015; 21:
361-8.
22.- Harpsøe MC, Basit S, Andersson M,
Nielsen NM, Frisch M, Wohlfahrt J, et al.
Body mass index and risk of autoimmune
diseases: a study within the Danish
National Birth Cohort. Int J Epidemiol
2014; 43: 843-55.
23.- Revelo XS, Luck H, Winer S, Winer DA.
Gastroenterol. latinoam 2017; Vol 28, Nº 3: 177-184